Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?

Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?Enzalutamide, apalutamide, or darolutamide: are apples or bananas best for patients?, Published online: 30 April 2019; doi:10.1038/s41585-019-0186-2The PROSPER, SPARTAN, and ARAMIS trials demonstrated the efficacy of enzalutamide, apalutamide, and darolutamide, respectively, to extend metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer. However, questions remain regarding patient selection for these agents, particularly concerning adverse effects, patient PSA doubling time, and cost and formulary considerations.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research